Therapy-related myelodysplastic syndrome (MDS)/AML (t-MDS/AML) is a common and devastating complication of treatment with alkylating agents and topoisomerase II inhibitors, often employed with curative intent, in standard or high doses, in the treatment of hematological malignancies and solid tumors. Allogeneic hematopoietic stem cell (HSC) transplant is considered the best treatment for t-MDS/AML 1 but its use is limited by the unavailability of donors, comorbidities in the recipient and risk of acute and chronic GVHD. The results of autologous HSC transplantation in t-MDS/AML are poor with an excessive rate of relapse; 2 likely reflecting the infusion of an HSC product carrying the same molecular abnormalities responsible for the development of the t-MDS/AML in the first place.
Patients with malignancies commonly treated with highdose chemotherapy and autologous HSC transplant (such as multiple myeloma and non-Hodgkin's lymphoma) who later develop t-MDS/AML occasionally undergo HSC transplant with stored HSC harvested prior to the diagnosis of the secondary malignancy (early-stored HSC) for the purpose of a future transplant to either consolidate an initial response or to be employed as salvage therapy for the primary malignancy. Such cells are theoretically less likely to carry the molecular 'hits' implicated in t-MDS/AML 3 than HSC harvested in first complete remission of the secondary malignancy. Another advantage is the prompt availability of the HSC product, avoiding the delay in the transplant process and toxicity caused by HSC mobilization and harvesting. Autologous HSC transplant utilizing a prestored product may therefore be an interesting option for patients with t-MDS/AML who lack an adequate HSC donor or are poor candidates to an allograft.
Between 2000 and 2007, six patients received early stored HSC transplant for treatment of t-MDS/AML at the Mayo Clinic, Rochester, MN, USA ( Table 1) . One of the patients have been reported in a prior publication. 4 Median age at the time of the transplant was 57 years (range 15-71). Three patients had been primarily diagnosed with follicular lymphoma, two with multiple myeloma and one with Ewing's sarcoma. All patients had prior exposure to alkylating agents that in all but one (patient 4) patient had first been administered prior to the harvesting (the same patient subsequently received an autologous HSC transplantation with Melphalan conditioning). Two patients had developed AML, one patient chronic myelomonocytic leukemia, one patient refractory cytopenias with multilineage dysplasia, one patient refractory anemia with excess of blasts 1 (RAEB1) and one patient RAEB2. In all cases, the chromosomal abnormalities known to be associated with t-MDS/AML 5 were identified. Median time from the diagnosis of the primary malignancy to HSC harvesting had been 26 (2-122) months and from harvesting to development of t-MDS/AML was 44 (10-79) months. Three of the patients received autologous transplantation shortly after the diagnosis of t-MDS. Both patients with t-AML received cytotoxic chemotherapy with complete response prior to transplantation and one patient with RAEB2 was treated with decitabine with hematological improvement. Conditioning regimen was CY and TBI in three patients, BU and CY in two patients and Samarium þ melphalan in one patient. Five patients reached criteria for neutrophil engraftment and four patients for platelet engraftment 10-34 and 13-126 days after transplant, respectively. The only patient not reaching criteria for neutrophil engraftment (patient 6) had been transplanted with active disease and had signs of progression of the AML 20 days after transplant. In three of six patients, there was disappearance of the pretransplant chromosomal abnormality (two patients À7 and one patient À7 and t (1;7) ). Two patients obtained hematologic CR and two patients obtained CR without full recovery of platelets. One patient died of sepsis 230 days after transplantation, one died with refractory disease on day 103 after transplant and one patient is alive with recurrence of t-MDS 17 months after transplantation. Three patients are alive 7, 73 and 87 months after transplant with no evidence of recurrence of the primary or secondary malignancy. Curiously, patient 1 had 20qÀ abnormality identified in the BM before the harvesting and at the time the patient presented with RAEB1. Despite the persistence of the chromosomal abnormality the patient has no evidence of recurrence of the t-MDS 87 months after transplantation. We conclude that myeloablative conditioning followed by early stored HSC transplant can provide prolonged survival for some patients with tMDS/AML with no available donors or not suitable to allogeneic HSC transplantation.
